Federal Register of Legislation - Australian Government

Primary content

PB 54 of 2012 Determinations/Health as made
This determination amends the National Health Act 1953 - Determination under section 84AH - Exempt items (No. PB 58 of 2007) to change the pharmaceutical items that are determined to be exempt items.
Administered by: Health
Registered 30 Jul 2012
Tabling HistoryDate
Tabled HR14-Aug-2012
Tabled Senate14-Aug-2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

 

PB 54 of 2012

Amendment Determination under section 84AH of the National Health Act 1953 (2012) (No. 2)

 

National Health Act 1953

___________________________________________________________________________

 

I, ADRIANA PLATONA, Assistant Secretary, Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of

The Minister for Health, make this instrument under section 84AH of the National Health Act 1953.

Dated                 27               July 2012

 

 

 

 

 

 

 

 

 

 

 

ADRIANA PLATONA

Assistant Secretary

Pharmaceutical Evaluation Branch

Pharmaceutical Benefits Division

Department of Health and Ageing

___________________________________________________________________

 

 

 

 

 

1              Name of Instrument

 

(1)                This Instrument is the Amendment Determination under section 84AH of the National Health Act 1953 (2012) (No. 2).

 

(2)                This Instrument may also be cited as PB 54 of 2012.

 

2              Commencement

                            This Instrument commences on 1 August 2012.

3              Amendments to PB 58 of 2007

                      Schedule 1 amends the legislative instrument titled Determination under section 84AH of the National Health Act 1953 (PB 58 of 2007) (as amended).

.

 


Schedule 1                   Amendments

 

      

 

[1]   Schedule 1, after entry for Clozapine Oral liquid 50 mg per mL, 100 mL:

            insert:

 

Cefuroxime

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

Oral

 

[2]        Schedule 1, after entry for Terbinafine Cream containing terbinafine hydrochloride 10 mg per g, 15 g:

            omit:

 

Tipranavir

Oral liquid 100 mg per mL, 95 mL

Oral

    

 

 

 

 

 

 

 

 

 

 

 

 

 

     

 

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.